About: Subjective utility ratings of neuroleptics in treating schizophrenia

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Subjective utility ratings of neuroleptics in treating schizophrenia Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 November 1990

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в листопаді 1990 (uk) im November 1990 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en payares de 1990 (ast) scientific article published on 01 November 1990 (en)
publication date	wds:Q68166794-5635BCD6-7506-4CFD-A9D2-F565231F7226
publication date	1990-11-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q68166794-6E74CB95-165B-4D10-AD22-A03172BC9C26
language of work or name	English
cites work	wds:Q68166794-199A8D08-5243-4AC7-B588-F171AA92B0E5 wds:Q68166794-8567E619-456D-41DF-938B-4C777FCC646C wds:Q68166794-8D28D81D-8163-4DAB-8015-85BD205172CB wds:Q68166794-9AECB328-9731-4B9E-A282-A2493D800500 wds:Q68166794-A2951A7A-6CC3-456A-9475-9802D2332196 wds:Q68166794-AF6AD744-65CC-4F3C-8ECB-D3B49A79D4D3 wds:Q68166794-BF595A9F-A108-4E00-985C-125227C8F4B3 wds:Q68166794-E65F419B-68F4-4CE6-90A1-E6E3D51E95AC
cites work	Base rates, utilities, and DSM-III: shortcomings of fixed-rule systems of psychodiagnosis. Why do schizophrenic patients refuse to take their drugs? The two-syndrome concept: origins and current status Antecedent probability and the efficiency of psychometric signs, patterns, or cutting scores The treatment utility of assessment. A functional approach to evaluating assessment quality. Schizophrenia and other psychotic disorders in DSM-III Some observations on the use of tranquilizing drugs Utilities as base-rate multipliers in the determination of optimum cutting scores for the discrimination of groups of unequal size and variance.
author name string	wds:Q68166794-4967325D-C48F-43D5-A049-EBE767ACFB58 wds:Q68166794-4EAB3332-49C6-4301-82AA-6DEE654DA1D4 wds:Q68166794-580BD70B-A242-4268-8292-29141497CC46 wds:Q68166794-9E3057CC-7995-4E02-90A8-FF26BAD9D9FE
author name string	J M Bailey R Faber R T Schultz S E Finn
rdfs:label	Subjective utility ratings of neuroleptics in treating schizophrenia (en) Subjective utility ratings of neuroleptics in treating schizophrenia (nl)
skos:prefLabel	Subjective utility ratings of neuroleptics in treating schizophrenia (en) Subjective utility ratings of neuroleptics in treating schizophrenia (nl)
name	Subjective utility ratings of neuroleptics in treating schizophrenia (en) Subjective utility ratings of neuroleptics in treating schizophrenia (nl)
title	wds:Q68166794-20422D94-FF17-45F4-93E0-31AB72B0867E
title	Subjective utility ratings of neuroleptics in treating schizophrenia (en)
page(s)	wds:Q68166794-AF1900F1-B9F8-4A02-A072-0D069FAC5DED
page(s)	843-848
instance of	wds:Q68166794-0A0DD6F4-6AD7-4925-94B4-7B2A6785C2E0
instance of	scholarly article
main subject	wds:Q68166794-3CC967BB-E531-47CC-AA55-7E9E5328FEC5
main subject	schizophrenia
PubMed ID	wds:Q68166794-4EC927A5-9EF1-4DF0-A8CC-A7F511AE9EE9
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/1980954
PubMed ID	1980954
published in	wds:Q68166794-0F154FFF-6E2D-416D-B8AF-CBDDE3BDDB41
published in	Psychological Medicine
issue	wds:Q68166794-F97915DF-9512-4011-AA3F-24643D30E91F
volume	wds:Q68166794-07FBDB95-C8D6-4C86-BFE5-FFC65638BEAC
issue	4
volume	20
DOI	wds:Q68166794-AC5A0972-AB90-46DD-9DBF-055102A9024F
DOI	http://dx.doi.org/10.1017/S0033291700036539
DOI	10.1017/S0033291700036539
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q68166794
is cites work of	Prolactin and schizophrenia: clinical consequences of hyperprolactinaemia Cure or curse? Ambivalent attitudes towards neuroleptic medication in schizophrenia and non-schizophrenia patients Adverse effects of antipsychotic drugs: survey of doctors' versus patients' perspective. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management Antipsychotic-induced sexual dysfunction and its management Comparison of preferences for health outcomes in schizophrenia among stakeholder groups. Sexual dysfunction in schizophrenia: focus on recent evidence Sexual dysfunction and antipsychotic treatment What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning? Sexual function and gonadal hormones in patients taking antipsychotic treatment for schizophrenia or schizoaffective disorder. Preferences for different insomnia treatment options in people with schizophrenia and related psychoses: a qualitative study The facts about sexual (Dys)function in schizophrenia: an overview of clinically relevant findings The meaning and management of neuroleptic medication: a study of patients with a diagnosis of schizophrenia. Health values of patients with bipolar disorder. The side effects of antipsychotic drugs and patients' quality of life: patient education and preference assessment with computers and multimedia. Health state preferences of persons with anxiety. An innovative approach to clinical communication in schizophrenia: the approaches to schizophrenia communication checklists Factors associated with self-rated sexual function in Korean patients with schizophrenia receiving risperidone monotherapy Quetiapine: efficacy and tolerability in schizophrenia Second generation antipsychotics improve sexual dysfunction in schizophrenia: a randomised controlled trial The ANNSERS (Antipsychotic Non-Neurological Side Effects Rating Scale): Validation of Sexual Side-Effect Measurement Tolerability of antipsychotic drugs: does patient perspective deserve consideration? Subjective experience and related symptoms in schizophrenia. Sexual dysfunction: The unspoken side effect of antipsychotics Aripiprazole use combined with depot antipsychotic medication: two cases demonstrating its ability to reduce prolactin levels in an adolescent forensic hospital The role of consumer perspectives in estimating population need for substance use services: a scoping review.
is cites work of	wds:Q34761446-17F696A9-F554-4879-99F0-FF6957A4C720 wds:Q35847530-4470813B-E610-450E-A0DB-DBC6FA012421 wds:Q51969966-12FD9A79-9F74-4341-BA89-0040AE67FD55 wds:Q51976505-064BAA79-EAFC-480D-9A56-27A9B7453995 wds:Q37078998-948C1365-61C7-4114-8E0B-9239EF27990D wds:Q36192428-3A76C32D-831A-4717-A85A-2BAC99FABB4D wds:Q45943453-B1AF8217-6B15-4B5B-9EDA-F9CCAE68B3A4 wds:Q34530080-6B9C0832-42DD-4E60-BA2A-E78D3674DDB4 wds:Q51108373-AC53C17F-3539-458E-9994-A4B39B68CFFA wds:Q35089945-DA22F6EA-AC9C-4CAC-8243-D309A49ED117 wds:Q35369968-6854CA7C-817B-4748-8D47-3667F9C7A9AE wds:Q36315422-CE9508C9-D4D4-44B2-95C5-9A3F3B13BFA6 wds:Q50156460-07E8569F-F08F-4EEA-9220-AA247904F0EB

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software